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Abstract
Lymphangiogenesis is a common phenomenon observed during inflammation and engraftment of transplants, but its
precise role in the immune response and underlying mechanisms of regulation remain poorly defined. Here we showed that
in response to injury and autoimmunity, lymphangiogenesis occurred around islets and played a key role in the islet
inflammation in mice. Vascular endothelial growth factors receptor 3 (VEGFR3) is specifically involved in lymphangiogenesis,
and blockade of VEGFR3 potently inhibited lymphangiogenesis in both islets and the draining LN during multiple low-dose
streptozotocin (MLDS) induced autoimmune insulitis, which resulted in less T cell infiltration, preservation of islets and
prevention of the onset of diabetes. In addition to their well-known conduit function, lymphatic endothelial cells (LEC) also
produced chemokines in response to inflammation. These LEC attracted two distinct CX3CR1
hi and LYVE-1
+ macrophage
subsets to the inflamed islets and CX3CR1
hi cells were influenced by LEC to differentiate into LYVE-1
+ cells closely associated
with lymphatic vessels. These observations indicate a linkage among lymphangiogenesis and myeloid cell inflammation
during insulitis. Thus, inhibition of lymphangiogenesis holds potential for treating insulitis and autoimmune diabetes.
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Introduction
Lymphatics undergo growth and remodeling during many
pathophysiological processes [1,2,3,4,5], and contribute to immu-
nity during tumor growth and metastases [1,2]. However, little is
known about the mechanisms regulating lymphatics during
inflammation, nor how lymphatics influence the progression of
immune response. Islets had been considered to lack functional
lymphatic vessels [6]. However, studies in NOD mice show that
lymphatic vessels are adjacent to inflamed islets [7,8] and a
functional lymphatic network is also found in transplanted islets
[9], suggesting peri- and intra-islet lymphatics might be involved in
regulating islet inflammation. However, the significance of islet
lymphangiogenesis and its contribution to islet inflammation
remains elusive.
With the identification of relatively specific lymphatic markers
such as VEGFR3, LYVE-1 [10], podoplanin [11], and Prox-1
[12], and the development of anti-lymphatic agents, the
mechanisms of lymphatic function have started to be elucidated
[13,14]. VEGFR3 is present in all endothelia during early stages of
development, and Vegfr3 gene-targeted mice die at around E10.5
due to defective development of the cardiovascular system [2,15].
The expression of VEGFR3 becomes restricted exclusively to LEC
with the exception of corneal dendritic cells and some angiogenic
blood vessels in tumors and healing wounds [15,16]. Vascular
endothelial growth factors VEGF-C and -D are the most potent
inducers of lymphatic growth via VEGFR3 [13,14,17,18]. VEGF-
A, the primary blood angiogenic factor binding to VEGFR2,
signals the major pathway to activate angiogenesis [13,14]. VEGF-
C also binds to VEGFR2, which is expressed predominantly on
blood vessels, but also to a small extent on lymphatic vessels
[18,19]. A recent study showed that both VEGFR2 and VEGFR3
mediate VEGF-A induced inflammatory cutaneous lymphangio-
genesis [20]. Lymphangiogenesis can be inhibited by VEGF-C/-D
trap, neutralizing anti-VEGFR3 antibodies, or tyrosine kinase
inhibitors, such as sunitinib, which inhibit VEGFR3 signaling
[21].
Here, we explored the roles of lymphangiogenesis and
lymphatic conduit function in islet inflammation. We showed that
lymphangiogenesis occurred both in inflamed islets and the
draining LNs, and prevention of diabetes was associated with
inhibition of lymphangiogenesis. The production of potent
lymphangiogenic and chemotactic molecules by LEC which
attracted the myeloid cells linked inflammation and lymphangio-
genesis. Inhibition of lymphangiogenesis decreased macrophage
and T cell infiltration, preserved islet architecture and function,
and prevented diabetes. These findings demonstrate important
and novel communications between the myeloid and lymphatic
systems to regulate adaptive immune responses.
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Mice
BALB/c and C57BL/6 mice were from Jackson Laboratory
(Bar Harbor, ME). CX3CR1
GFP/GFP on the C57BL/6 and BALB/
c backgrounds were from Dr. Littman (Skirball Institute, New York,
NY).CX3CR1
GFP/GFPC57BL/6micewerecrossed with C57BL/6
mice to produce CX3CR1
GFP/+. All mice were housed in a
pathogen-free animal facility and all efforts were made to minimize
suffering. Mice were anesthetized with carbon dioxide. All
experimental protocols involving mice were approved by the
Institutional Animal Care and Utilization Committee of University
of Maryland Medical Center (protocol # 0610003 and 0610004).
Diabetes Induction and Agent Administration
Male BALB/c mice (8–10 weeks old) were given intraperitoneal
injections of streptozotocin (STZ, Sigma-Aldrich, St. Louis, MO),
at a dose of 40 mg/kg daily for 5 consecutive days. Animals were
considered diabetic when blood glucose were .300 mg/dl for 2
consecutive days. FTY720 was from Dr. V. Brinkmann (Novartis
Pharma, Basel, Switzerland). Rat anti-VEGFR3 mAb (mF4-31C1)
was from Dr. B. Pytowsky (ImClone Systems, New York, NY)
[22]. Sunitinib (sunitinib malate, SU-11248-L) was from Dr. James
Christensen (Pfizer, Inc., Groton, CT). ALK1-Fc (ALK1 human
IgG1) was previously described [23]. Control human-IgG1, rat
IgG1 (HRPN) and rat anti-VEGFR2 mAb (DC101) were from Bio
X Cell (West Lebanon, NH). The dose of treatment chosen for
each was based on previous experience: FTY720 (1 mg/kg) and
sunitinib (40 mg/kg) were administered by oral gavage (once daily)
[24,25], and PBS, anti-VEGFR3 (32 mg/kg) [22,26], rat IgG1
(35 mg/kg), and anti-VEGFR2 mAb (35 mg/kg) [20] were
administered by intraperitoneal injection (3 times per week), for
2 weeks starting from the first STZ injection. Activin receptor-like
kinase 1 (ALK1)-Fc and human IgG1 (10 mg/kg) was adminis-
tered by intraperitoneal injection twice weekly for 4 weeks starting
from the first STZ injection [23].
Immunofluorescent staining and quantitative image
analysis
Hand-picked islets were incubated with anti-LYVE-1 and
FITC-anti-CD31, followed by Cy5-conjugated goat anti-rabbit
IgG, and then mounted with Vectashield (with DAPI) (Vector
Laboratories, Inc., Berlingame, CA). Eight-10 mm frozen sections
of LNs and pancreas were fixed by acetone. Cultured cells grown
on chamber slide were fixed by 4% paraformaldehyde. After
blocking with PBS/5% donkey serum, sections were incubated
with primary antibodies, and followed by secondary antibodies in
PBS/1% donkey serum, and sections were mounted with
Vectashield. Purified rat anti-peripheral LN addressin (PNAd,
MECA79), American hamster anti-CD3e (145-2C11), rat anti-
MECA32 and rat anti-CD31 (390) were from BD Biosciences-
Pharmingen (San Jose, CA). Guinea pig anti-swan insulin was
from Dako Cytomation, Inc. (Carpinteria, CA). Purified rabbit
anti-LYVE-1 was from Fitzgerald Industries International, Inc.
(Concord, MA). Purified rat anti-CD68 (FA-11) was from AbD
Serotec, MorphoSys UK Ltd (Oxford, UK). Cy5 or Cy3-
conjugated goat anti-rabbit IgG, DyLight488 or DyLight649-
conjugated donkey anti-rabbit IgG, Cy3 or DyLight488-conju-
gated goat anti-hamster IgG, DyLight649-conjugated donkey anti-
rat IgG, FITC-conjugated goat anti-rat IgM and Cy3-conjugated
goat anti-guinea pig IgG were from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). Images were acquired with a
Leica DMRA2 fluorescent microscope (Leica Microsystems,
Wetzlar GmbH, Germany), and Openlab or Volocity (Improvi-
sion, Inc., MA). Quantitative analysis was performed with Image J
(NIH, Bethesda, MD) or Volocity. Two-five tissue sections from
each pancreas or LN were randomly chosen. In each section of
pancreas, all islet-centered areas (about 350–450 pixels at 2006
magnification to the edge of islet) were selected and the specific
positively staining areas were measured by Image J software. The
areaswithinand aroundisletsweremanuallyseparatedaccordingto
DAPI and insulin staining. The areas covered by CD3 or insulin
staining inside the islet boundaries were measured respectively, and
expressed as a percentage of the whole islet area. The areas covered
by LYVE-1 around the islet were measured as the density of
lymphatic vessels and expressed as a percentage of the whole area
outside of the islet. The positive areas for blood vessels (MECA32
+)
within or around the islet weremeasured separately, and the density
was expressed as a percentage of the whole islet areas or the whole
outside areas. CD68
+LYVE-1
2 cells and CD68
+LYVE-1
+ cells
touching islets were manually counted with Volocity. The
circumference of each islet was measured by Volocity. Macrophage
numbers of per mm in each islet from each group were compared.
LN lymphatic vessels and HEVs were measured as LYVE-1 or
PANd positively staining areas by Image J, respectively; and
expressed as a percentage of the whole LN area.
Flow cytometry
Pancreata were digested with 8 mg/ml collagenase-D (Roche
Diagnostics, Indianapolis, IN) with 10 mg/ml DNase I (Sigma) for
60 minutes at 37uC. Granulocytes, erythrocytes and dead cells
were removed by Ficoll-Paque (GE Healthcare, Piscataway, NJ)
density gradient centrifugation. Pancreatic cells were resuspended
in PBS containing 1% BSA, 2 mg/ml FcR-blocking buffer
(eBioscience Inc., San Diego, CA) and 1 mM EDTA, and stained
with antibodies at 4uC. Fluorescent or biotin labeled antibodies
against mouse podoplanin (8.1.1), CD31 (390), CD45 (30-F11),
CD11b (M1/70), F4/80 (BM8), LYVE-1 (ALY7) and CD11c
(N418) were from eBioscience. Fluorescent- or biotin-labeled anti-
CD68 (FA-11) were from AbD Serotec. CD68 was stained
extracellularly and subsequently intracellularly with the Cytofix/
Cytoperm kit (BD) according to the manufacturer’s protocol. Flow
cytometric analyses were performed on an LSRII flow cytometer
(BD) with FlowJo (Tree Star Inc.). Dead cells were excluded by
DAPI (Invitrogen) staining.
Pancreatic macrophage and LEC isolation
CX3CR1
hiGr1
medLYVE-1
2 and CX3CR1
loGr1
medLYVE-1
hi
macrophages, and CD45
2LYVE-1
+ LEC were isolated from
pancreatic single-cell suspensions from normal or MLDS treated
CX3CR1
GFP/+ mice by Aria II flow cytometer (BD). Sorted cells
were spun onto the slides, and stained with Wright’s stain (Sigma)
after methanol fixation.
Tube formation
Sorted CX3CR1
hi macrophages and lymphocytes (CD45
+CD
11b
2Gr1
2) were labeled with CFSE (Invitrogen), and LYVE-1
+
macrophages were labeled with eFlour670 (eBioscience) before
culture. Matrigel (BD) diluted with EBM-2 Endothelial Basal
Medium (Lonza Inc., Walkerville, MD) (Matrigel:EBM-2, 2:1) was
added to 8-well chamber slides (LAB-TEK, Naperville, IL) and
allowed to gel at 37uC. For mixed cultures, 5610
4 CX3CR1
hi
macrophages-CFSE, 5610
4 LYVE-1
+ macrophages-eFlour670,
5610
4 lymphocytes-CFSE and/or 1610
4 LEC in Endothelial Cell
Growth Medium-2 were then seeded onto the Matrigel and
cultured for 5 days. For staining, 1610
5 CX3CR1
hi macrophages-
CFSE with/without 1610
4 LEC were directly seeded onto CC
2
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CD11b and LYVE-1.
Quantitative real-time PCR (qRT-PCR)
The procedures for RNA isolation, cDNA synthetic and
quantification by qRT-PCR were described previously [24]. qPCR
used Oligo(dT) primers on a the LightCycler 2.0 (Roche) machine.
Relative expression was calculated as 2
cycle threshold [Ct] control – Ct gene
using cyclophilin A as an endogenous control. Primer sequences for
CCR8, forward 59-TGACCGACTACTACCCTGATTTCTT-39
and reverse 59- GCTGCCCCTGAGGAGGAA-39; CCL2 forward
59-GATCCCAATGAGTAGGCTGG-39and reverse 59-CGGGT-
CAACTTCACATTCAAAG-39; CCL3 forward 59-CCAAGTCT-
TCTCAGCCAT-39 and reverse 59-TCCGGCTGTAGGAGAA-
GCAG-39; CCL4 forward 59-CCACTTCCTGCTGTTTCTCT-
39 and reverse 59-CACAGATCTGTCTGCCTCTT-39; CCL5,
forward 59-CAAGTGCTCCAATCTTGCAGTC-39 and reverse
59-TTCTCTGGGTTGGCACACAC-39; CCL8 forward 59-ACA-
ATATCCAGTGCCCCATG -39 and reverse 59-GATGAGAAA-
ACACGCAGCC-39; CXCL10 forward 59-CCTGCTGGGTC-
TGAGTGGGA-39 and reverse 59-GATAGGCTCGCAGGGAT-
GAT-39; CX3CL1 forward 59-ACAAGATGACCTCACGAAT-
CC-39 and reverse 59-TCCACCCGCTTCTCAAAC-39, CCL21
forward 59-GGGAACCTCTAAGTCTGGAAAG-39 and reverse
59-GGCTCCTGAGTCTGTTTTCTAG-39. Other primers were
from previous publications [24,27].
Statistical Analysis
Each histological parameter was measured in a blinded fashion.
The differences were assessed using unpaired Student’s t test and
expressed as the mean 6 standard deviation (SD). A Value of
p,0.05 was taken to be statistically significant. Diabetic incidence
curves were constructed with Kaplan-Meier estimates and
analyzed by the generalized Wilcoxon’s test.
Results
MLDS-induced islet inflammation causes
lymphangiogenesis
To examine the vascular and lymphatic networks, isolated islets
were stained for the lymphatic and blood endothelial markers
LYVE-1 and CD31, respectively. A CD31
+ blood vessel network
was contained within normal naive islets, while LYVE-1
+
lymphatic vessels surrounding some of islets penetrated only into
the hilum (Figure 1A). To investigate the role of islet lymphatic
vessels in diabetes, BALB/c mice were rendered diabetic by
MLDS, which induces islet inflammation and T cell dependent
autoimmunity [28]. Mice were treated with anti-VEGFR3 mAb,
sunitinib, or FTY720 starting on the first day of STZ administra-
tion. Pancreata were examined 7–13 days after treatment by
immunofluorescent staining for insulin, LYVE-1 and CD3. MLDS
caused T cell infiltration, islet destruction and loss. LYVE-1
+
lymphatic vessels around the islets increased after MLDS,
demonstrating inflammation caused lymphangiogenesis. FTY720,
an S1P1 modulator [24] which has been shown to prevent diabetes
in NOD mice and islet rejection [29,30], prevented loss of insulin
+
cells, T cell infiltration and lymphangiogenesis, demonstrating that
lymphangiogenesis is involved in islet inflammation. Both anti-
VEGFR3 mAb, which specifically targets LEC growth receptors,
and sunitinib, which inhibits the kinase activity of VEGFR3,
inhibited islet lymphangiogenesis, reduced or prevented loss of
insulin
+ cells and reduced T cell infiltration (Figure 1B–1C). MLDS
didnot inducebloodvenuleangiogenesiswithinoraroundthe islets,
and FTY720, sunitinib and anti-VEGFR3 mAb did not influence
blood vessel density (Figure 1D–1E). Thus, blood vessel angiogen-
esis was not induced and angiogenesis was less important for
MLDS-induced islet inflammation. Since sunitinib can also inhibit
kinases involved in blood vascular angiogenesis, this showed that
sunitinib prevented islet inflammation mainly through inhibiting
lymphangiogenesis. The effects of these inhibitors on existing
lymphatic and blood vessels were examined in non-inflamed tissues.
Neither lymphatic nor blood vessel density around the islets were
influenced by FTY720, sunitinib or anti-VEGFR3 in normal mice,
demonstrating that these reagents inhibited inflammation-induced
lymphangiogenesis, but did not affect existing lymphatic and blood
vessels (Figure 1F–1G). Overall, prevention of beta-cell loss
correlated with inhibition of lymphangiogenesis rather than a
change in angiogenesis in islets.
LNs play key roles in inflammation and immune responses [31].
As expected the pancreatic draining LNs of treated mice enlarged,
and sunitinib and FTY720 inhibited this LN response (Figure 2A).
Draining LNs were evaluated for lymphangiogenesis and high
endothelial venule (HEV) angiogenesis by staining for LYVE-1
and PNAd, respectively. MLDS stimulated LN lymphangiogenesis
(Figure 2B–2C), but did not cause HEV vascular angiogenesis;
inhibition of inflammation with the immunosuppressant FTY720
inhibited LN lymphangiogeneiss but not HEV angiogenesis,
suggesting that LN lymphangiogeneis was more related to islet
inflammation than HEV angiogenesis. Both sunitinib and anti-
VEGFR3 mAb prevented LN lymphangiogenesis. Sunitinib and
anti-VEGFR3 mAb also both markedly reduced the extent of
PNAd
+ HEVs, likely reflecting the utilization of VEGFR3 by
blood vascular endothelial cells [17,18]. LN responses are the
result of a number of distinct factors and LN responses were likely
reduced both by inhibiting upstream islet lymphangiogenesis and
conduit function, and downstream intranodal lymphangiogenesis.
Together these results demonstrated a tight association between
tissue and LN lymphatic function and lymphangiogenesis.
Inhibition of lymphangiogenesis prevents MLDS-induced
diabetes
To define the role of lymphangiogenesis in diabetes, we
investigated the roles of distinct lymphangiogenic and angiogenic
inhibitors in MLDS induced diabetes. As shown in Figure 3A,
blood glucose levels increased by 10 days after STZ initiation.
Similar to FTY720, both anti-VEGFR3 mAbs and sunitinib
completely prevented hyperglycemia (Figure 3A). ALK1 is a
member of the transforming growth factor-b type I family of
receptors and is primarily expressed in the developing vascular
system, blockade of ALK1 signaling results in defective lymphatic
vascular development and ALK1-Fc blocks its function [23].
ALK1-Fc also prevented diabetes in over 80% of mice (Figure 3B).
Thus, inhibition of lymphangiogenesis or lymphatic development
prevented MLDS induced insulitis and autoimmune diabetes. In
contrast, anti-VEGFR2 mAb delayed the day of onset and only
decreased but did not prevent the incidence of hyperglycemia
(Figure 3C), preventing MLDS induced diabetes in only 30% of
treated mice (Figure 3D), indicating that blockade of VEGFR2
prevented insulitis to a much lesser extent compared to blockade of
VEGFR3.
Lymphatic endothelial cells produce chemokines and
VEGFs
To dissect the events linking inflammation and lymphangiogen-
esis, whole pancreas was examined for expression of inflammatory
mediators. Total RNA from pancreata before and on day 7 after
MLDS was assayed. Levels of CCL8 and CXCL10 were increased
Lymphangiogenesis Is Required for Islet Immunity
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e28023Figure 1. MLDS-induced islet inflammation causes lymphangiogenesis. MLDS treated BALB/c mice received FTY720, sunitinib, or anti-
VEGFR3 mAb starting from the first STZ injection. (A) Whole mount immunohistochemistry of isolated normal islets of BALB/c mice. Blood vessels:
CD31; lymphatic vessels: LYVE-1. Scale bar: 200 pixels. 2006magnification. (B) Immunofluorescent analysis of beta-cells (insulin), T cells (CD3) and
lymphatic vessels (LYVE-1) in pancreas 7 days or 13 days after initiation of MLDS treatment. Scale bars: 32 mm. (D) Immunofluorescent analysis of
beta-cells (insulin), blood vessels (MECA32) and lymphatic vessels (LYVE-1) 7 days after initiation of MLDS treatment. Scale bars: 32 mm. (C) and (E)
Quantitative analysis of insulin, CD3, LYVE-1 and MECA32 staining of pancreas 7 days after initiation of MLDS treatment. 12–15 islets for insulin and
CD3, 12–15 areas around islets for LYVE-1, and 14–21 islets or areas around islets for MECA32; 2 slides/mouse; 2–4 mice/group. * P#0.05, ** P#0.01,
*** P#0.001; ns, not significantly. (F) and (G) Normal BALB/c mice received indicated treatment for 7 days. (F) Immunofluorescent analysis of beta-cells
Lymphangiogenesis Is Required for Islet Immunity
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28023by 8- to 12-fold after MLDS treatment, and CCL2 and CCL4
were increased by 2- to 3-fold (Figure 4A). Importantly, CCL2, 4,
8 and CXCL10 recruit monocytes/macrophages and T cells to
sites of tissue injury and inflammation [32], suggesting MLDS-
induced tissue damage directly facilitated monocyte and T cell
infiltration. We previously demonstrated by gene-array analysis
that LEC line SVEC4-10 expressed various chemokines at
baseline and in response to inflammatory stimuli, suggesting that
LEC may be a source of chemokine in MLDS [24]. Therefore, we
examined the expression of chemokines and VEGFs in freshly
isolated pancreatic LECs, which were obtained before and on day
3 after MLDS. Pancreatic LEC expressed podoplanin (Figure 4B)
and VEGFRs (Figure 4C) and formed tube-like structures in
culture (Figure 4B), demonstrating their LEC phenotype. Expres-
sion of mRNA for CCL2 and CCL21 was observed, and after
MLDS treatment CCL21 increased significantly and CCL2
increased less so. The expression of other chemokines was also
observed. LEC expressed all three VEGFs. After MLDS, VEGF-D
expression significantly increased (Figure 4C). These data
supported the notion that LEC responded to initial inflammatory
signals by producing chemokines that recruited additional
inflammatory cells and by producing VEGFs that promoted
lymphangiogenesis, thus contributing to islet inflammation in a
paracrine manner.
LEC attract two macrophage subsets which contribute to
lymphangiogenesis and islet inflammation
Macrophages have been shown to play a role during the
development of diabetes [33,34,35]. Recent reports also suggest
that CD11b
+Gr1
+ macrophages contribute to lymphangiogenesis
in trachea [36], cornea [37,38], skin [39] and tumors [40]. We
analyzed macrophage phenotype in pancreas in normal mice. As
shown in Figure 5A, the majority of pancreatic CD11b
+ cells were
Gr1
med. The Gr1
medCD11b
+ population was further divided by
Figure 2. Inhibition of lymphatic function alters draining LN size and prevents MLDS induced LN lymphangiogenesis. MLDS treated
BALB/c mice received FTY720, sunitinib, or anti-VEGFR3 mAb starting from the first STZ injection. Mice were euthanized 7 days after initial MLDS
treatment. (A) Weight (n=5 mice/group) and cell number (pooled 2 LNs) of draining pancreatic LNs. (B) Immunofluorescent analysis of T cells (CD3),
lymphatic vessels (LYVE-1) and HEVs (PNAd) in pancreatic LNs 7 days after initiation of MLDS treatment. 1006magnification. (C) Quantitative analysis
of LYVE-1 and PNAd staining in draining pancreatic LNs. 2 slides/mouse, 2–4 mice/group. Mean 6 SD. * P#0.01, **, P#0.001.
doi:10.1371/journal.pone.0028023.g002
(insulin), lymphatic vessels (LYVE-1) and blood vessels (MECA32). 2006magnification. (G) Quantitative analysis of LYVE-1 and MECA32 staining of
pancreas. 18–21 areas around islets; 2 slides/mouse; 2–4 mice/group. P.0.1 vs untreated mice. Mean 6 SD. 2006magnification.
doi:10.1371/journal.pone.0028023.g001
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defining CX3CR1
hi (CX3CR1
hiLYVE-1
2) and LYVE-1
+
(CX3CR1
loLYVE-1
+) subsets. Both subsets expressed the macro-
phage markers F4/80 and CD68. Wright’s stain showed that both
subsets were mononuclear with a large nucleus and vacuolar
cytoplasm (Figure 5B), indicative of macrophages. Ten-20% of the
CX3CR1
hi subset also expressed low levels of CD11c, suggesting
subset heterogeneity. The LYVE-1
+ subset expressed higher levels
of F4/80 and CD68, and had more and larger vacuolar
cytoplasm. The two subsets expressed similar levels of the LEC
marker podoplanin and the endothelial marker CD31. Chemokine
receptor expression showed that two subsets expressed comparable
levels of CCR2, CCR5, CCR7 and CCR8 (Figure 5C). Since LEC
expressed the CCR7 ligand CCL21, which was up-regulated
during islet inflammation, this indicated that LEC had the
potential to attract macrophages. The CX3CR1
hi subset expressed
higher VEGF-C. The LYVE-1
+ subset, but not the CX3CR1
hi
subset, expressed CCL21 and also expressed higher levels of CCL2
and CCL4. Both subsets expressed the VEGFR3 but not the
VEGFR1 or VEGFR2 blood endothelial markers. These results
suggested that the pancreas contained at least two phenotypically
distinct macrophage populations, and suggested the CX3CR1
hi
subset could sustain lymphangiogenesis through VEGF-C, while
the LYVE-1
+ subset resembled LEC in their LYVE-1
+ phenotype
and by expressing multiple inflammatory chemokines to attract
additional myeloid cells.
LEC cultured on Matrigel formed cord-like structures in vitro
(Figure 4B), whereas macrophages distributed evenly in the culture
in the absence of LEC (Figure 6A). When macrophages and LEC
were co-cultured, both subsets became elongated, and lined up
with and/or integrated into the cord-like structures of the LEC
(Figure 6A); In contrast, lymphocytes remained rounded and were
mostly found outside the LEC cords (Figure 6A). This indicated
that LEC attracted and interacted with both macrophage subsets.
Immunofluorescent staining of tissues (Figure 6B) showed that
LYVE-1
+CD68
+ cells were lining or incorporated into lymphatic
vessels in the pancreas. Isolated CFSE labeled CX3CR1
hi
macrophages were cultured with pancreatic LEC for 5 days.
Staining for LYVE-1 showed that 50% of CX3CR1
hiCD11-
b
+LYVE-1
2 macrophages became LYVE-1
+ after co-culture with
LEC, but this change was not observed in the absence of LEC
(Figure 6C). Thus, the CX3CR1
hi subset differentiated into the
LYVE-1
+ subset in a process dependent on LEC, while tightly
associating with or integrating into LEC cord structures in vitro
and in vivo. After MLDS induced inflammation, the LYVE-1
+
macrophages surrounding islets significantly increased (Figure 7A–
7B), suggesting LYVE-1
+ macrophages migrated to the inflamed
islets. Both sunitinib and anti-VEGFR3 inhibited LYVE-1
+
Figure 3. Inhibition of lymphatic function prevents diabetes by MLDS treatment. (A) MLDS treated BALB/c mice received FTY720, sunitinib,
or anti-VEGFR3 mAb starting from the first STZ injection for 2 weeks. Blood glucose profiles, compared to control of MLDS treated mice receiving the
indicated treatments. P-values for all groups compared to control, ,0.001. (B) Incidence of diabetes. MLDS treated mice received ALK1-Fc, control
human IgG1 or PBS starting from the first STZ injection for 4 weeks. (C and D) MLDS treated BALB/c mice received anti-VEGFR2 mAb or control rat
IgG1 starting from the first STZ injection for 2 weeks. (C) Blood glucose profiles, p-values all ,0.05, anti-VEGFR2 compared to rat IgG1 or normal. (D)
Incidence of diabetes, p=0.0002.
doi:10.1371/journal.pone.0028023.g003
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ing that blockade of lymphangiogenesis reduced inflammation and
inhibited recruitment of LYVE-1
+ macrophages. Together, these
data showed that LEC had the ability to recruit macrophages and
influence their differentiation, while macrophages had the
potential to sustain lymphangiogenesis and inflammation through
the production of VEGFs and chemokines.
Discussion
Islet inflammation occurs during type 1 diabetes and islet
rejection, but the underlying mechanisms are not fully understood.
In this study, we found that lymphangiogenesis played a pivotal
role in MLDS induced islet inflammation and autoimmune
insulitis. Blockade of lymphangiogenesis by anti-VEGFR3 as well
as sunitinib inhibited insulitis, preserved islet beta-cells and
prevented MLDS induced diabetes.
In contrast, other reports show blockade of VEGFR3 promotes
the inflammatory process in chronic arthritis [41] and cutaneous
inflammation in keratin 14-VEGF-A transgenic mouse models
[20,41], and specific activation of lymphatic vessels by overex-
pression of VEGF-C or VEGF-D, or by injection of VEGF-C
attenuates inflammatory edema in both chronic and acute
cutaneous inflammation models [20,42]. It should be noted that
there are abundant cutaneous lymphatic vessels present in the
steady-state, and these reports [20,42] demonstrated lymphatic
vessel drainage and lymph flow are impaired during inflammation.
Increased delivery of VEGF-C to the skin restores lymphatic
function and improves edema resolution [20,42]. Unlike skin, islets
are largely devoid of lymphatic vessels in the steady-state. We
observed that lymphangiogenesis was associated with T cell and
macrophage infiltration during islet inflammation and blockade of
VEGFR3 reduced inflammatory cell infiltration. Thus, in our
model lymphangiogenesis contributed to the influx of an
inflammatory infiltrate, while in the other models lymphangiogen-
esis overcame the dysfunction of lymphatics and contributed to the
export of inflammatory cells and the resolution of inflammation.
Our findings in this acute autoimmune inflammation model are in
agreement with results of a previous study using an islet allogeneic
transplantation model [43] and a corneal transplantation model
[38], which showed inhibition of lymphangiogenesis prevented
immune-mediated graft rejection. Lymphangiogenesis in kidney
transplant is also associated with inflammatory lymphocytic
infiltrates and transplant rejection [44]. Numerous CCR7
+ cells
are observed within the transplant kidney nodular and seem to be
attracted by CCL21 released by LEC [44]. We also found that
chemokines and VEGFs were up-regulated in LEC during islet
inflammation. CCL21 expression in LEC is associated with
activation of LEC via VEGFR3 signaling in cardiac allografts
[45]. LPS-TLR4 signaling in LEC results in the production of
various chemokines for chemotaxis of macrophages [46]. Besides
CCL21, other mononuclear and T cell chemotactic factors were
also up-regulated in LEC and the SVEC4-10 cell line (data not
shown) in response to inflammatory stimuli. Thus lymphangiogen-
esis and activation of LEC have the potential to enhance leukocyte
homing to the lymphatic vessels by affecting the chemotactic
gradients [47], and enhance the initiation and maintenance of
alloimmune and autoimmune responses in transplantation and
MLDS-induced diabetes.
Figure 4. Expression of VEGFs and chemokines by pancreas and lymphatic endothelial cells. (A) mRNA expression of chemokines in
pancreas of MLDS treated BALB/c mice determined by qRT-PCR before treatment and on day 7. Values expressed as fold change. 3 mice/group, data
representative of 2 separate experiments. (B) Flow sorting gates. LEC gated on FSC-A vs SSC-A, FSC-A vs FSC-W, CD45
+, DAPI
2, CD31
+/2 and LYVE-1
+.
Right upper panel, sorted LEC (LYVE-1
+CD31
+/2CD45
2) cultured on Matrigel for 5 days. 1006 magnification. (C) mRNA expression profile of
chemokines and VEGFs in sorted pancreatic LEC. CD45
2CD31
+/2LYVE-1
+ cells sorted from normal or MLDS treated CX3CR1
GFP/+ (day 3 after initial
treatment), 6–7 mice/group. Data representative of 2 separate experiments. PCR performed in triplicate. * P#0.05, ** P#0.01, *** P#0.001. All data
are represented as mean 6 SD.
doi:10.1371/journal.pone.0028023.g004
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appear within the islets of NOD mice [34] and are required for the
development and activation of the cytotoxic T cells that cause
beta-cell destruction [35]. To our knowledge, this is the first
characterization of pancreatic macrophage subsets in the pancre-
as. Our results showed that LEC attracted these macrophages and
influenced the CX3CR1
hi subset differentiation into the LYVE-1
+
subset. The two subsets displayed different phenotypes; the former
produced higher VEGF-C and the latter displayed a lymphatic
endothelial phenotype. Recent studies in transplantation, wound
healing and tumor models show that macrophages are involved in
lymphangiogenesis by secreting VEGFs to stimulate lymphatic
vessel sprouting, and by differentiating into LEC and incorporat-
ing into lymphatic vessels [27,39,48,49]. Thus recruited macro-
phages may enhance the lymphangiogenesis. Monocyte/macro-
phage infiltration also happens during cutaneous inflammation,
and inhibition of VEGFR3 signaling decreases macrophage
infiltration. Thus, macrophage infiltration seems associated with
inflammation in the cutaneous inflammation model [20,42].
Although the total number of macrophages in the whole pancreas
did not change (data not shown), the number of LYVE-1
+
macrophages significantly increased around inflamed islets and
inhibition of lymphangiogenesis prevented LYVE-1
+ macrophage
infiltration. Thus newly formed lymphatics and activated LEC
seemed able to induce relocation of macrophages within the
pancreas to the inflamed islet. We propose a model where, under
inflammatory stimuli, tissue LEC secrete chemokines and
cytokines that recruit macrophages and influence their function.
Blood vessel angiogenesis caused by MLDS-induced islet
inflammation was not observed until day 7, when macrophage
and T cell infiltration, and lymphangiogenesis had already
appeared. This implied that angiogenesis was not the main event
that initiated islet immune responses. Blockade of VEGFR2,
whose signaling is the major pathway that activates angiogenesis
[13,14,15], delayed the progression of insulitis and partially
prevented the onset of MLDS-induced diabetes. VEGFR2 has
Figure 5. Phenotype of pancreatic macrophages. (A) Identification of macrophage subsets in pancreas of CX3CR1
GFP/+ C56BL/6 mice.
Pancreatic single cell suspensions were gated on FSC-A vs FSC-W and CD45
+. Histograms show receptor expression profile of CX3CR1
hiLYVE-1
2
(green line) and CX3CR1
loLYVE-1
+ (red line) macrophages. (B) Sorted CX3CR1
loLYVE-1
+ and CX3CR1
hiLYVE-1
2 macrophages spun onto glass slides and
stained with Wright’s stain. 10006 magnification. (C) mRNA expression profile of chemokine receptors, chemokines and VEGFs in pancreatic
macrophage subsets. mRNA levels examined by qRT-PCR in duplicate or triplicate. 6–7 mice/group, data representative of 2–4 separate experiments.
doi:10.1371/journal.pone.0028023.g005
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hi macrophages, LYVE-1
+ macrophages, CD11b
2-lymphocytes and LEC
were sorted from pancreatic single cell suspensions of CX3CR1
GFP/+ mice. Co-cultured CX3CR1
hi macrophages-CFSE, LYVE-1
+ macrophages-eFlour670,
or lymphocytes-CFSE with/without LEC on Matrigel for 5 days. Scale bars: 60 mm. 1006magnification. (B) Immunofluorescent staining of CD68 and
LYVE-1 in pancreas from C57BL/6 mice. Scale bars: 160 mm. 506magnification. (C) Sorted CX3CR1
hi macrophages labeled with CFSE and co-cultured
with LEC (left upper panel) or without LEC (left lower panel) for 5 days, and stained for CD11b (red) and LYVE-1 (yellow). Scale bars: 10 mm. 6306
magnification. Right panel, quantitative analysis, total cells from 5 fields (134461024 pixels) were counted. All data representative of 2 to 4 separate
experiments.
doi:10.1371/journal.pone.0028023.g006
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contribute to lymphangiogenesis during inflammation [18,19,20].
Thus, anti-VEGFR2 treatment might affect lymphangiogenesis
but not to the same degree as anti-VEGFR3. VEGFR2 signals also
regulate vascular permeability and adhesion molecules, and might
further regulate immune response [50,51].
The expression of VEGFR3 is restricted to LEC with few
exceptions [13,14,16,52]. Although one report showed VEGFR3
transcripts were detected in some human T cell lines [53], whether
VEGFR3 expressed on surface of T cells remains to be proven and
to our knowledge direct effects of VEGFR3 signaling on the
function of leukocytes has not been reported. VEGFR3 expression
was detected in these macrophages at the mRNA level, so it is
possible that anti-VEGFR3 treatment directly altered macrophage
recruitment and this needs further investigation. In this study, in
addition to anti-VEGFR3 mAb, sunitinib was also used to
interfere with lymphatic functions. Sunitinib is a potent anti-
angiogenic and anti-lymphangiogenic kinase inhibitor that targets
multiple tyrosine kinase receptors, including VEGFR, PDGFR, c-
kit, and FLT3 [21,25,54], and is clinically approved for treatment
of malignancies [54]. Recent reports use tyrosine kinase inhibitors
for prevention of diabetes and diabetic complications [55,56].
Louvet et al. [55] showed that sunitinib reversed new onset
diabetes in NOD. They suggested that sunitinib inhibited
PDGFR, although this specificity was not proven. So it also
possible that sunitinib altered T cell recruitment or activation
during islet inflammation. FTY720 is an agonist and antagonist for
the S1P receptors [24,57]. It has been reported that S1P induces
lymphangiogenesis by stimulating the migration and differentia-
tion of LEC via an S1P1/Gi/PLC/Ca
2+ signaling pathway [58].
Thus, FTY720 may have acted as an S1PR antagonist to inhibit
LEC.
In summary, the results here suggest interplay between LEC
and macrophages, with the former producing chemokines that
attract the latter, which in turn express more chemokines and
VEGFs to amplify lymphangiogenesis. Our study demonstrates
that lymphangiogenesis plays a crucial role in insulitis suggesting
that modulating islet lymphangiogenesis may serve important
therapeutic effects in diabetes.
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